Table of Contents
1. REPORT PROLOGUE
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Breakdown of Primary Respondents
3.5. Forecasting Techniques
3.6. Research Methodology for Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Porter’s Five Forces Analysis
5.1.1. Bargaining Power of Suppliers
5.1.2. Bargaining Power of Buyers
5.1.3. Threat of New Entrants
5.1.4. Threat of Substitutes
5.1.5. Intensity of Rivalry
5.2. Value Chain Analysis
5.3. Regulatory Framework
6. GLOBAL ANTIBIOTIC RESISTANCE MARKET, BY DRUG CLASS
6.1. Overview
6.2. Oxazolidinones
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.3. Lipoglycopeptides
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.4. Tetracyclines
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.5. Cephalosporins
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.6. Combination therapies
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.7. Others
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7. GLOBAL ANTIBIOTIC RESISTANCE MARKET, BY DISEASE
7.1. Overview
7.2. Complicated Urinary Tract Infection (cUTI)
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.3. Blood Stream Infections (BSI)
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.4. Complicated Intra-Abdominal Infections (cIAI)
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.5. Clostridium difficile infections (CDI)
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.6. Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.7. Hospital-Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.8. Community-Acquired Bacterial Pneumonia (CABP)
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.9. Others
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
8. GLOBAL ANTIBIOTIC RESISTANCE MARKET, BY PATHOGEN
8.1. Overview
8.2. Staphylococcus Aureus
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
8.3. Streptococcus pneumoniae
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
8.4. Acinetobacter
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
8.5. Enterococcus faecium
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
8.6. Hemophilus Influenzae
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
8.7. Pseudomonas aeruginosa
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
8.8. Clostridium difficile
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
8.9. K. pneumoniae
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
8.10. Others
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
9. GLOBAL ANTIBIOTIC RESISTANCE MARKET, BY END USER
9.1. Overview
9.2. Hospitals & Clinics
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
9.3. Research Organizations
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
9.4. Others
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
10. GLOBAL ANTIBIOTIC RESISTANCE MARKET, BY REGION
10.1. Overview
10.2. Americas
10.2.1. North America
10.2.1.1. US
10.2.1.2. Canada
10.2.2. Latin America
10.3. Europe
10.3.1. Western Europe
10.3.1.1. Germany
10.3.1.2. France
10.3.1.3. Italy
10.3.1.4. Spain
10.3.1.5. UK
10.3.1.6. Rest of Western Europe
10.3.2. Eastern Europe
10.4. Asia-Pacific
10.4.1. Japan
10.4.2. China
10.4.3. India
10.4.4. Australia
10.4.5. South Korea
10.4.6. Rest of Asia-Pacific
10.5. Middle East & Africa
10.5.1. Middle East
10.5.2. Africa
11. COMPANY LANDSCAPE
11.1.1. Overview
11.1.2. Competitive Analysis
11.1.3. Market Share Analysis
11.1.4. Major Growth Strategy in the Global Antibiotic Resistance Market
11.1.5. Competitive Benchmarking
11.1.6. Leading Player in terms of Number of Developments in Global Antibiotic Resistance Market
11.1.7. Key Developments & Growth Strategies
11.1.7.1. Product Launch
11.1.7.2. Merger & Acquisition
11.1.7.3. Joint Ventures
11.1.8. Major Players Financial Matrix
11.1.8.1. Sales & Operating Income 2020
11.1.9. Major Players R&D Expenditure 2020
12. COMPANY PROFILES
12.1. Achaogen, Inc.
12.1.1. Company Overview
12.1.2. Product Overview
12.1.3. Financial Overview
12.1.4. Key Developments
12.1.5. SWOT Analysis
12.1.6. Key Strategies
12.2. Basilea Pharmaceutica Ltd.
12.3. MELINTA THERAPEUTICS, INC.
12.4. PARATEK therapeutics
12.5. Seres Therapeutics
12.6. Theravance Biopharma.
12.7. Entasis Therapeutics
12.8. Tetraphase Pharmaceuticals
12.9. Nabriva Therapeutics plc
12.10. NEMESIS BIOSCIENCE LTD
12.11. Procarta Biosystems
12.12. Allecra Therapeutics
12.13. Others
13. APPENDIX
13.1. References
13.2. Related Reports
NOTE:
This table of content is tentative and subject to change as the research progresses.
• In section 10, only top companies will be profiled. Each company will be profiled based on the Market Overview, Financials, Product Portfolio, Business Strategies, and Recent Developments parameters.
• Please note: The financial details of the company cannot be provided if the information is not available in the public domain and or from reliable sources.
